Spero Therapeutics, Inc. announced that it has entered into a securities purchase agreement with new investor Pfizer Inc. for private placement of 2,362,348 common shares $16.93 per share for gross proceeds of $39,994,551.64 on June 30, 2021. The company has raised funding as part of the Pfizer Breakthrough Growth Initiative. The company received funding from 1 investor pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 USD | -2.96% | +0.61% | +11.56% |
Mar. 13 | Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
Mar. 13 | Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.56% | 88.38M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- SPRO Stock
- News Spero Therapeutics, Inc.
- Spero Therapeutics, Inc. announced that it has received $39.994552 million in funding from Pfizer Inc.